webinar register page

Webinar banner
Pharma - Chronic and Autoimmune Disorders
Chronic non-communicable diseases now account for three quarters of annual deaths worldwide, with a fast rising percentage taking place in low and middle income countries. With this in mind, how important is incentivizing more industry investment in costly clinical trials and other research targeting key areas of unmet need in major chronic conditions like CVD? Will a better understanding of the common molecular signatures that underlie many serious autoimmune disorders result in more progress in therapeutic interventions, including prevention?

Oct 26, 2022 01:00 PM in Eastern Time (US and Canada)

Webinar logo
* Required information
Loading

Speakers

AbbVie Inc.
Dr. Sarah Akerman
Executive Medical Director @Alkermes, Inc.
Sarah Akerman, MD is a psychiatrist and executive medical director in medical affairs at Alkermes with over six years of experience in the pharmaceutical industry. In her current role, she oversees the medical strategy for the neuroscience program, which includes treatments for bipolar disorder, schizophrenia, and substance use disorders. She received a Bachelor of Arts from Tufts University and a Doctor of Medicine from the University of Miami Miller School of Medicine where she was a member of the Alpha Omega Alpha Honor Medical Society. She completed a psychiatry residency, served as chief resident and completed addiction clinical and research fellowships at the Dartmouth Geisel School of Medicine. Following fellowship, she established a treatment program for pregnant women with substance use disorders and received a Dartmouth SYNERGY Scholars research award prior to joining industry.
Dr. Volker Knappertz
Executive Vice President of Research & Development @Aurinia Pharmaceuticals, Inc.
Dr. Volker Knappertz is the Executive Vice President of Research & Development, joining Aurinia in July 2022. He leads the entirety of Aurinia’s R&D effort, including pre-clinical research and pharmacology, clinical development, patient safety, medical affairs, regulatory affairs, and all other R&D functions. Dr. Knappertz is a recognized leader in the drug development community and has achieved numerous INDs and product approvals. He served on several committees involving pharmaceutical, regulatory and academia medicine development. His work has been published in leading peer reviewed journals, including Proceedings of the National Academy of Sciences, JAMA Neurology, Lancet Neurology, BMJ and Neurology. He currently serves as an independent director on the board of Sutura Therapeutics, UK, an innovation-driven company developing RNA-targeted precision gene medicines to treat debilitating or life-threatening medical conditions.
Vlad Coric, MD
Chief Executive Officer and Chairman @Biohaven Pharmaceuticals
In eight years as CEO of Biohaven, Dr. Coric has led the company in the pursuit of its bold vision to advance novel medications to underserved patients with devastating neurological and neuropsychiatric diseases. His leadership has translated into the dramatic growth of Biohaven from an entrepreneurial start-up into a modern, publicly-traded company that has developed therapies that change millions of patients’ lives and yielded a doubling of value for investors since its initial public offering in 2017. Today, Biohaven is valued at over $9 billion with approximately 1,000 employees. The pillars of the company’s success — Commitment to Patients, Winning Science, and Responsibility to Investors — continue to be the hallmark of Biohaven’s ongoing growth under Dr. Coric’s stewardship.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly & Co.
Bev Incledon, PhD
Chief Scientific Officer and Executive Vice President @Ironshore Pharmaceuticals, Inc.
Dr. Incledon serves as Ironshore’s Chief Scientific Officer. He has been instrumental in designing Ironshore’s novel drug delivery technology and developing and managing its clinical programs. He has over 28 years of pharmaceutical industry experience encompassing large and small molecule drug discovery, pre-clinical, clinical, product and manufacturing process development roles as well as new R&D facility start-up and research on novel drug delivery technology. Dr. Incledon gained these experiences through roles at Syntex Inc., Glaxo Wellcome Inc., Eli Lilly and Company, and several start-up biotech companies. Over his career he has contributed to 21 products in the clinical development stage and 8 marketed products.
Merck & Co.
Pfizer Inc.
Sanskriti (Sans) Thakur
Chief Growth Officer @Medable
Sanskriti (Sans) Thakur serves the life sciences industry with executive experience across scientific development, corporate and commercial strategy, with early stage digital and medical technology management. Sans is currently the Chief Growth Officer for Medable, the leading technology platform for clinical development. She is focused on corporate growth to advance the company’s vision of human-centered research, enabling remote access to clinical trials regardless of geography, income, and race. In her journey with Medable she has helped the company grow over 300%. Beyond her professional titles, she serves with the Global Future Council of the World Economic Forum focusing on data and innovations in healthcare. Sans is a thought leader in issues ranging from modern healthcare, women’s health, clinical trials, to patient advocacy. She is the author of over 18 publications in the areas of science, business and technology intersections.